English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

Arsenic trioxide has recently been found to improve survival and complete response when added to all-trans retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia (APL). However, dose-limiting toxicity in the form of druginduced QT prolongation limits its use in a significant percentage of patients. Preclinical models of long QT syndrome (LQTS) have demonstrated that glucocorticoids can significantly shorten the duration of the cardiac action potential. However, the relevance of these findings is unclear in human populations. Here we report the protective effects of glucocorticoid administration on QT interval in a case of APL treated with arsenic trioxide.

Dexamethasone suppresses long QT phenotype in patient with acute promyelocytic leukemia treated with arsenic